HUMDF Stock Chart & Stats
$0.34
-$0.03(-7.57%)
At close: 4:00 PM EDT
$0.34
-$0.03(-7.57%)
Day’s Range― - ―
52-Week Range$0.25 - $0.62
Previous CloseN/A
Volume500.00
Average Volume (3M)83.00
Market Cap
$300.31M
Enterprise Value$1.29K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$301.80M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume150
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$131.52M
Bulls Say, Bears Say
Bulls Say
Differentiated Commercial ProductAn already marketed, first-in-class glucokinase activator gives Hua Medicine a differentiated commercial foothold in China’s type 2 diabetes market. Product sales can build recurring prescription revenue as patient uptake, indication expansion and market penetration develop over time.
Improving Revenue And Gross MarginAcceleration in 2025 revenue and a materially higher gross margin indicate improving product economics and commercial traction. If this combination persists, it can create more contribution per sale and provide a stronger base for funding pipeline development, even before operating profitability is reached.
Improved Balance-Sheet PositionDebt-to-equity of about 0.30 and equity of roughly 1.01B in 2025 indicate a more stable capital base than in 2024, when equity was negative. Broadly stable total debt also limits balance-sheet deterioration and preserves flexibility while the company pursues commercialization.
Bears Say
Operating Profitability Remains NegativeDespite stronger revenue and gross margin, 2025 operating margin was about -29.4% and EBITDA margin about -22.8%. Current operating losses show the commercial model has not yet reached self-sustaining profitability, leaving future growth dependent on improving scale and cost absorption.
Negative And Volatile Cash GenerationOperating cash flow of about -52M and free cash flow of about -60M in 2025 show that reported business activity is not currently converting into cash. The reversal from exceptionally strong 2023 cash generation to cash burn in 2024–2025 raises funding pressure and weakens internal financing capacity.
Uncertain Earnings QualityA strongly positive 2025 net margin alongside continuing operating losses indicates that reported earnings may not be generated mainly by the core business. This reduces confidence in profit repeatability and makes sustainable earnings power harder to establish until operating results improve.
Hua Medicine News
HUMDF FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was $0.25 and its highest was $0.62 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is $300.31M.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 204 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Aug 20, 2026. The company reported -$0.004 earnings per share for the quarter.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -$0.004 in its last earnings report. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HUMDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
HUMDF Company Deck
HUMDF Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.59% Public Companies and
Individual Investors